Global Dermatitis Market Is Expected to Grow at a CAGR of Approximately 9% Over 2018-2022: The Business Research Company

News provided by

Nov 07, 2019, 10:00 ET

LONDON, Nov. 7, 2019 /PRNewswire/ -- Strict government regulations are restraining the dermatitis drugs market growth. Atopic Dermatitis (eczema) usually occurs at a very early stage (0-5 years). In order to find the efficacy and efficiency of a drug, it has to be tried on every type of patient. The effects of certain drugs on adults are quite different from the effects on children, due to which results of the clinical trial cannot be used for the production of a drug that will be used for children. This hinders research and requires more efforts in clearing regulations set by the Food and Drug Administration (FDA). For example, as the patient population is largely children, the FDA in its CFR Code Title 21, Part 50 Protection of Human Subjects, and subpart D, has laid down guidelines for the additional safeguard of children in clinical investigation. The regulation is in compliance with Children's Health Act of 2000, that requires all the children subjected to clinical trials to be given additional protection.

Read More On The Business Research Company's Dermatitis Drugs Market Report:

https://www.thebusinessresearchcompany.com/report/dermatitis-drugs-global-market-report

Major Regulatory Bodies In The Dermatitis Drugs Market

The dermatitis drugs market is governed by several regulatory bodies that require drug manufacturers to get approvals from the concerned authorities before launching their medicines into the market. Two such major regulatory bodies are the Pharmaceuticals and Medical Devices Agency (PMDA) (Japan) and the Central Drugs Standard Control Organisation (CDSCO) (India), that carry out quality checks before declaring the drugs suitable for consumption. The PMDA reviews the products with an aim to ensure safety, quality and efficacy of pharmaceuticals and then approves the products that are suitable in every parameter. Similarly, the CDSCO is the central drug authority that is responsible for the approval of new drugs in India. These tedious approval processes make the drugs more effective and safer for consumption.

Increasing Prevalence Of Atopic Dermatitis

Dermatitis drugs include corticosteroids, calcineurin inhibitors, and PDE4 inhibitors which are used to cure inflammation of the outer layer of the body, characterized by itchy rashes on swollen and reddened skin. Major dermatitis drugs include Triamcinolone, Clobetasol, Betamethasone, Hydrocortisone, Fluocinonide and Clobex. The global dermatitis drugs market was valued at about $17.88 billion in 2018 and is expected to grow to $25.52 billion at an annual growth rate of 9.3% through 2022. Growth in the atopic dermatitis market is primarily driven by the increasing global prevalence of the disease. Prevalence of dermatitis in children is estimated to be around 15-20% while it is 1-3% in adults. The increasing cases of food allergies are adding to the prevalence of dermatitis which ultimately leads to the increase in demand for the medicines to cure this disease. For example, a study conducted in Norway highlights that the overall incidence rate of atopic dermatitis has increased from 0.028 per person year in 2009 to 0.034 per person year in 2014.

Request A Free Sample Of The Dermatitis Drugs Market Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2413&type=smp

Players In The Dermatitis Drug Market Are Investing In Mergers And Acquisitions

Major players in the dermatitis drug market are LEO Pharma A/S, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc. and Sanofi S.A. The dermatitis market has witnessed an increasing number of Mergers and Acquisitions (M&As), done with the purpose of business expansion and increasing visibility. M&As are playing a significant role in today's world and are assumed to expand this market in the years to come. The vendors in this industry are focusing on collaboration and partnerships to expand their portfolio and improve market presence. Companies are also strategically making M&As with a view to reduce competition and increase the scalability of their business. For example, Stiefel Laboratories has been able to successfully widen its global reach after it was acquired by Glaxo Smith Kline. Also, Biofrontera, Inc., a specialist in the dermatology market, acquired Cutanea Life Sciences, Inc. in 2019 for $7.3 million to increase its capital base and scale the business.

Place A Direct Purchase Order Of Complete Report @ https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2413

View Similar Reports:

Pharmaceutical Drugs Market By Segments (Musculoskeletal Disorders Drugs, Cardiovascular Drugs, Oncology Drugs, Anti-Infective Drugs, Metabolic Disorder Drugs, Central Nervous System Drugs, Genito-Urinary Drugs, Respiratory Diseases Drugs, Gastrointestinal Drugs, Hematology Drugs, Dermatology Drugs, Ophthalmology Drugs) - Global Forecast To 2022 @ https://www.thebusinessresearchcompany.com/report/pharmaceutical-drugs-market

Dermatology Drugs Global Market Report 2019 @ https://www.thebusinessresearchcompany.com/report/dermatology-drugs-global-market-report

The World's Most Comprehensive Database:

The Business Research Company's Global Market Model analyzes all the above data and more. It is the world's most comprehensive database of integrated market information. The portal puts the understanding of global markets such as healthcare, manufacturing and technology in your hands, allowing you to compare and evaluate hundreds of different market opportunities across the globe at the touch of a button. Available through an online portal with a simple login, the portal tracks the size and growth of 2400+ global markets and 60 geographies including historic and forecast market values and competitor shares.

Interested to know more about The Business Research Company?

The Business Research Company has published over 300 industry reports, covering over 2400 market segments and 56 geographies. The reports draw on 150,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

Contact Information:

The Business Research Company

Nitin G
Email: [email protected]
Europe: +44-207-1930-708
Asia: +91-8897263534
Americas: +1-315-623-0293
Follow us on LinkedIn: https://in.linkedin.com/company/the-business-research-company
Follow us on Twitter: https://twitter.com/tbrc_Info
Blog: https://www.thebusinessresearchcompany.com/blogs.aspx
Press Release: https://www.thebusinessresearchcompany.com/press-release.aspx

SOURCE The Business Research Company